PsychedelicNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’

Cybin Corp., Canada’s leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme (“SAP”) access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health challenges with dignity,” said Cybin co-founder Paul Glavine in the press release. “Everyone at Cybin applauds the efforts of TheraPsil and these brave individuals, and we thank the Minister of Health for her foresight.”

To view the full press release, visit http://ibn.fm/FAtPL

About Cybin Corp.

Cybin is a life-sciences company advancing mushroom-based psychedelic and nutraceutical products for various psychiatric and neurologic conditions. Cybin is developing technology that seeks to improve bioavailability to achieve the desired effects of psychedelics at lower dosages. Cybin is developing products with new delivery systems and intends to support clinical trials to evaluate efficacy to potentially combat major depressive disorder and addiction and improve cognitive flexibility. For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended…

1 week ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition

NRx Pharmaceuticals (NASDAQ: NRXP), through its wholly owned subsidiary HOPE Therapeutics(TM), Inc., announced it has…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride from Ketamine Products

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed a Citizen Petition with the…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference

NRx Pharmaceuticals (NASDAQ: NRXP), announced that CEO and Chairman Prof. Jonathan Javitt, MD, MPH will…

4 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Charts Dual-Path for NRX-100 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and…

1 month ago